{
    "clinical_study": {
        "@rank": "364",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 09, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04302766"
        },
        "id_info": {
            "org_study_id": "S-20-01",
            "nct_id": "NCT04302766"
        },
        "brief_title": "Expanded Access Remdesivir (RDV; GS-5734\u2122)",
        "official_title": "Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734\u2122)",
        "sponsors": {
            "lead_sponsor": {
                "agency": "U.S. Army Medical Research and Development Command",
                "agency_class": "U.S. Fed"
            }
        },
        "source": "U.S. Army Medical Research and Development Command",
        "brief_summary": {
            "textblock": "Disease caused by 2019 Novel Coronavirus"
        },
        "detailed_description": {
            "textblock": "The treatment of communicable Novel Coronavirus (CODIV-19) of 2019 with Remdesivir (RDV;\n      GS-5734\u2122)"
        },
        "overall_status": "Available",
        "study_type": "Expanded Access",
        "expanded_access_info": {
            "expanded_access_type_intermediate": "Yes",
            "expanded_access_type_treatment": "Yes"
        },
        "condition": "Coronavirus Disease 2019",
        "intervention": {
            "intervention_type": "Drug",
            "intervention_name": "Remdesivir",
            "description": "Remdesivir (RDV,GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).",
            "other_name": "GS-5734"
        },
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  DoD-affiliated personnel as defined in DoDI 6200.02, which includes\n             emergency-essential civilian employees and/or contractor personnel accompanying the\n             Armed Forces who are subject to the same health risk as military personnel\n\n          -  Have a laboratory-confirmed COVID-19 diagnosis with moderate to severe disease\n             presentation as determined by the principal investigator\n\n          -  Patient or legally authorized representative (LAR) provides written informed consent,\n             except as noted in 21 CFR 50.23\n\n          -  Understands and agrees to comply with planned study procedures\n\n          -  Available for clinical follow-up for duration of the treatment and follow-up period\n\n          -  Woman of childbearing potential must\n\n               -  Have a negative pregnancy test within 24 hours before starting treatment\n\n               -  Agree not to become pregnant during treatment and for 1 months after receiving\n                  remdesivir (Treatment will be a maximum of 10 doses given over a 10-day interval)\n\n               -  Use at least 2 reliable forms of effective contraception, including 1 barrier\n                  method, during treatment and for 1 month after the treatment period\n\n        Exclusion Criteria:\n\n          -  ALT/AST \u2265 5 times the upper limit of normal\n\n          -  Stage 4 severe kidney disease or requiring dialysis (i.e. eGFR <30)\n\n          -  Anticipated transfer to another hospital that is not a study site within 72 hours\n\n          -  Allergy to any components of the study medication [GS-5734, sulfobutylether\n             \u03b2-cyclodextrin sodium (SBECD) and hydrochloric acid and/or sodium hydroxide]\n\n          -  Concomitant antiviral therapy (lopinavir/ritonavir [Kaletra])\n\n          -  Pregnant or nursing"
            },
            "gender": "All",
            "minimum_age": "N/A",
            "maximum_age": "N/A"
        },
        "overall_contact": {
            "last_name": "Sandi K Parriott",
            "phone": "301-619-6824",
            "email": "sandi.k.parriott.mil@mail.mil"
        },
        "verification_date": "March 2020",
        "study_first_submitted": "March 2, 2020",
        "study_first_submitted_qc": "March 6, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "March 10, 2020"
        },
        "last_update_submitted": "March 19, 2020",
        "last_update_submitted_qc": "March 19, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "March 20, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "keyword": [
            "COVID-19",
            "GS-5734",
            "Remdesivir"
        ],
        "condition_browse": {
            "mesh_term": "Coronavirus Infections"
        }
    }
}